

 <div style="text-align: center;"> <b>Financial Assistance Award</b>   <b>DENALI COMMISSION</b>          510 L Street, Suite 410          Anchorage, Alaska 99501          (907) 271-1414 (phone)          (907) 271-1415 (fax)          www.denali.gov       </div>		<b>Award Number</b>	01513-00		
		<b>Award Title</b>	Respiratory Syncytial Virus (RSV) Study		
		<b>Performance Period</b>	October 1, 2016 through December 31, 2018		
<b>Authority</b> 112 Stat 1854	<b>CFDA Number</b> 90.100	<b><u>Recipient Organization &amp; Address</u></b> Yukon Kuskokwim Health Corporation PO BOX 528 Bethel, AK 99559-0528  <b>Phone:</b> [NoPhoneRecord] <b>Recipient DUNS #</b> 082508961 <b>TIN #</b> 920041414			
<b>Denali Commission Finance Officer Certification</b>					
<b><u>Cost Share Distribution Table</u></b>					
Accounting Code	New Funding		Prior Period Funding		Total
	Denali Commission	Other Contributors	Denali Commission	Other Contributors	
95670000	\$334,780.00		\$0.00		\$334,780.00
	\$0.00		\$0.00		\$0.00
	\$0.00		\$0.00		\$0.00
	\$0.00		\$0.00		\$0.00
	\$0.00		\$0.00		\$0.00
		\$0.00		\$0.00	\$0.00
		\$0.00		\$0.00	\$0.00
		\$0.00		\$0.00	\$0.00
		\$0.00		\$0.00	\$0.00
<b>Total</b>	<b>\$334,780.00</b>	<b>\$0.00</b>	<b>\$0.00</b>	<b>\$0.00</b>	<b>\$334,780.00</b>
This Financial Assistance Award approved by the Federal Co-Chair of the Denali Commission constitutes an obligation of federal funding.					
<b>Signature of Authorized Official - Denali Commission</b>  Electronically Signed		<b>Typed Name and Title</b> Mr. Joel Neimeyer Federal Co-Chair		<b>Date</b> 11/30/2016	

# AWARD ATTACHMENTS

Yukon Kuskokwim Health Corporation

01513-00

1. Terms and Conditions
2. Attachment A
3. Budget & Funding Summary
4. Attachment B

**Financial Assistance Award Terms and Conditions  
Between the Denali Commission and Yukon Kuskokwim Health Corporation  
For Respiratory Syncytial Virus Study  
Award No. 1513**

**1. Project Summary**

- a. Scope of Work: Evaluate the contribution of respiratory syncytial virus (RSV) to respiratory related hospitalizations of Alaska Native adults in the Yukon Kuskokwim Delta region.
- b. Deliverables: Epidemiological report.
- c. Budget: The Commission is making \$334,780 available for the project via this Financial Assistance Award (FAA). These funds were transferred to the Commission by the Centers For Disease Control (CDC) via an Interagency Agreement under the authority of MAP 21. This amount includes all direct, indirect, and pre-award costs (if any) authorized pursuant to 2 CFR 200.458. All Commission funding is intended to be used for the scope of work identified in this FAA only. Any funds remaining after the full scope of work has been completed shall be returned to the Denali Commission consistent with 2 CFR 200.319.
- d. Delivery Method: Study of patients at the Yukon Kuskokwim Health Corporation (YKHC) Regional Hospital, in collaboration with CDC and the Alaska Native Tribal Health Consortium (ANTHC).
- e. Performance Period: The Period of Performance for this FAA is October 1, 2016 thru December 31, 2018. In accordance with 2 CFR 200.309 Recipients can only incur obligations or costs against this FAA during the Period of Performance, unless specifically authorized in the Special Provisions (Section 14 of this document). If a project cannot be completed within the approved Period of Performance, an extension request must be made in accordance with the Commission's *Recipient Guidelines and Requirements* (RGR) document dated July 2015, available at [www.denali.gov](http://www.denali.gov).

More detailed information on scope, deliverables, budget, funding, project delivery method and/or management plan, schedule and key milestones are included in Attachment A dated September 22, 2016 and Attachment B dated August 1, 2016.

## **2. Project Reporting and Commission Site Visits**

Progress reports and a close-out report are required under this FAA. Progress Reports shall be submitted at the frequency stipulated in the Special Provisions. The Closeout Report shall be completed within 90-days of the end of the Period of Performance. All reports must be submitted using the Denali Commission's on-line Project Database System, available at [www.denali.gov/dcpdb](http://www.denali.gov/dcpdb).

Commission staff or agents of the Commission may make visits to the project site and/or home office to monitor progress during and/or after the Period of Performance. The Recipient shall coordinate and make information available as necessary to facilitate any such site visits.

Refer to the *Recipient Guidelines and Requirements* document for further information related to reports and site visits.

## **3. Payments**

Payments under this FAA will be made in accordance with 2 CFR 200.305 by electronic transfer in response to a Standard Form 270 (SF-270) "Request for Advance or Reimbursement", submitted by the Recipient. At a minimum, all 270's must include summary cost information on labor, materials, contracts/consultants, and indirect costs. Detailed documentation is required for any single expenditure greater than \$50,000. If Pre-award Costs and/or Advance Payments are authorized under this FAA, the Special Provisions will indicate so. Requests for reimbursements may be made as needed. Refer to the *Recipient Guidelines and Requirements* document for further information about submitting SF-270's.

## **4. Modifications**

In accordance with 2 CFR 200.308, the Recipient shall report deviations in project scope, budget, delivery method, management plan, schedule, or changed site conditions, and request prior approvals from the Program Manager. The Recipient shall also submit written requests to the Program Manager for the replacement of Key Staff identified in the Special Provisions. Refer to the *Recipient Guidelines and Requirements* document for further information about modifying a Financial Assistance Award.

## **5. Financial Management, Record Keeping, Internal Controls, and Audits**

The Recipient must have financial management and record keeping systems that are consistent with 2 CFR 200.302. If the Recipient is a State organization it must expend and account for FAA funds in accordance with applicable State laws and procedures for expending and accounting for the State's own funds.

The Recipient must establish and maintain effective internal controls with respect to this FAA that are consistent with 2 CFR 200.303.

In accordance with 2 CFR 200.501, Recipients that expend \$750,000 or more of federal funds in a year shall have a single or program-specific audit conducted for that year.

Refer to the *Recipient Guidelines and Requirements* document for further information about financial management, record keeping, internal controls and audits.

## **6. Direct and Indirect Costs**

All direct costs must be allowable and reasonable. Indirect costs must be allocable based on accepted accounting policies and practices. Indirect costs must be specifically included as a line item or identified with appropriate notes in the approved FAA budget. Refer to 2 CFR 200 Subpart E (Cost Principles) and the *Recipient Guidelines and Requirements* document for further information on direct and indirect costs.

## **7. Sub-Awards and Contracts**

All sub-awards and contracts issued by the Recipient under this FAA must comply with 2 CFR 200.331 and Appendix II to 2 CFR 200. Refer to the *Recipient Guidelines and Requirements* document for further information on this subject.

## **8. Acknowledgement of Support**

The Recipient shall name the Denali Commission as a financial contributor and project/program partner in all media correspondence related to the work supported by this FAA. If Commission funds are used for construction, the Recipient shall also display a sign at the construction site that acknowledges the Commission's support. Refer to the *Recipient Guidelines and Requirements* document for further information on this subject.

## **9. Real and Personal Property**

In accordance with 2 CFR 200.311, 313, and 316 the Denali Commission may require the Recipient to execute a security interest or other public notice of record to indicate that real or personal property acquired or improved, in whole or in part, with Federal funds is subject to a Federal interest. Any such requirements under this FAA, including post project reporting in accordance with 2 CFR 200.329, will be stipulated in the Special Provisions.

## **10. Conflict of Interest**

In accordance with 2 CFR 200.112, the Recipient must disclose in writing any potential conflicts of interest to the Commission. In addition, 2 CFR 200.318 requires that Recipients maintain written standards of conduct covering conflicts of interest and governing the performance of their employees engaged in the selection, award, and administration of contracts. Refer to the *Recipient Guidelines and Requirements* document for further information on this subject.

### **11. Denali Commission Policies**

Recipients may be required to comply with certain published Denali Commission policies. Any such requirements under this FAA will be stipulated in the Special Provisions. Refer to the *Recipient Guidelines and Requirements* document for further information on individual policies.

### **12. Laws and Regulations**

Recipients are required to comply with all applicable Federal laws and regulations. General categories of potentially applicable laws and regulations are summarized below. Refer to the *Recipient Guidelines and Requirements* document for further information on specific laws and regulations that may apply.

- a. Debarment and Suspension
- b. Whistle-blower Protection
- c. Non-Discrimination
- d. Lobbying and Propaganda
- e. Environmental
- f. Drug-Free Workplace
- g. Travel
- h. Human Rights
- i. Animal Welfare
- j. Executive Compensation

### **13. Other Provisions**

- a. The United States expressly disclaims any and all responsibility or liability to the Recipient or sub-recipients for the actions of the Recipient or sub-recipients resulting in death, bodily injury, property damages, or any other losses resulting in any way from the performance of this FAA, including sub-awards, contracts, or sub-contracts issued in connection with this FAA.
- b. To the maximum extent practicable, considering applicable laws, the Recipient shall accomplish the project contemplated by this FAA using local Alaska firms and labor.
- c. All terms and conditions contained in this FAA apply to any sub-recipient under this FAA.
- d. Failure to comply with the provisions of this FAA or maintain satisfactory performance may result in additional FAA conditions pursuant to 2 CFR 207. This includes but is not limited to: temporarily withholding of payments pending the correction of the deficiency; disallowance of project costs; wholly or partially suspending or terminating the FAA. In addition, failure to comply with the provisions of this FAA may also have a negative impact on the Recipient's eligibility for future Federal awards.

#### **14. Special Provisions**

Progress Reports: Semi-annually, with each report covering two quarters of the federal fiscal year for the duration of the performance period.

Pre-award Costs: Back to 1 October 2016

Key Staff: Investigators identified in Attachment B

Advance Payments: n/a

Federal Property Interests and Reporting Requirements: n/a

Denali Commission Policies: n/a

Bonds and Insurance: n/a

#### **15. Program Manager, Financial Manager & Other Contact Information**

<b>Denali Commission</b>	<b>YKHC</b>
Jay Farmwald Program Manager 510 L Street, Suite 410 Anchorage, AK 99501 Phone: 907-271-1414 Fax: 907-271-1415 E-mail: jfarmwald@denali.gov	Dr. Joseph Klejka Project Manager PO Box 528 Bethel, AK 99559-0528 Phone: 907-543-6028 Fax: 907-543-6029 Email: joseph_klejka@ykhc.org
Janet Davis Grants Management Officer 510 L Street, Suite 410 Anchorage, AK 99501 Phone: 907-271-3036 Fax: 907-271-1415 E-mail: jdavis@denali.gov	Sherry Smith Director of Finance Operations PO Box 528 Bethel, AK 99559-0528 Phone: 907-543-6942 Fax: 907- 543-6029 Email: sherry_smith@ykhc.org

**Attachment A  
To The  
Financial Assistance Award Terms and Conditions  
Between the Denali Commission and Yukon Kuskokwim Health Corporation  
For RSV Study  
Award #1513**

- a. Scope of Work: Reference Attachment B dated 1 August 2016
- b. Deliverables: Reference Attachment B dated 1 August 2016
- c. Budget: The Commission is making \$334,780 available for the project via this Financial Assistance Award (FAA). These funds were transferred to the Commission by the Centers For Disease Control (CDC) via an Interagency Agreement under the authority of MAP 21. Detailed budget and funding information is summarized on page 2.
- d. Delivery Method: Reference Attachment B dated 1 August 2016
- e. Schedule: The period of performance for this project is 1 October 2016 thru 31 December 2018. Key milestones are summarized below.

Start Study: 1 January 2017  
Complete Study: 31 December 2018  
Closeout Report: 31 March 2019



BUDGET				
Line	Item	By	Amount	Basis/Notes
1	Research Nurse	YKHC	\$113,963	0.5 FTE
2	Research Assistant	YKHC	\$40,955	0.5 FTE
3	Nurse and Assistant Fringe Benefits	YKHC	\$46,476	30% of lines 1 and 2
4	Investigator	ANTHC	\$19,344	0.1 FTE
5	Subtotal		\$220,738	
6	Lab Test Supplies	YKHC	\$34,000	\$85/specimen x 200 tests/yr x 2 yrs
7	Participant Incentives	YKHC	\$14,000	400 each \$35 gift cards
8	Travel	ANTHC & CDC	\$6,000	2 trips @ \$3,000 each
9	Indirect Costs	YKHC	\$60,041	27.2% of line 5
10	Total		\$334,779	
11	Rounded		\$334,780	

Additional Notes

a. YKHC has a federally negotiated indirect rate of 27.2% dated 25 November 2014 from the US Department of Health and Human Services

FUNDING				
Line	Source	Award or Reference	Amount	Notes
12	Denali Commission	This Action	\$334,780	CDC funds provided to Commission via IAA - 16FED1612371
13	Total Funding Available As Of This Action		\$334,780	

Interagency Agreement  
Between  
Centers for Disease Control and Prevention and  
Denali Commission

Attachment B  
1 August 2016

**IAA 16FED1612371**

**Title:** Active surveillance for respiratory syncytial virus in hospitalized Alaska Native adults from the Yukon Kuskokwim Delta region.

**Investigators:** Rosalyn Singleton MD MPH, Karen Rudolph PhD, , Thomas Hennessy MD, Joseph Klejka MD, Prabhu Gounder MD, Michael Bruce MD, Lisa Bulkow MS, Susan Gerber, Janet Englund MD, Helen Y Chu MD, Larry Anderson MD. Arctic Investigations Program, YKHC, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control; CDC, OI, NCIRD; University of Washington, Emory University.

**Background:** Alaska Native infants from the Yukon Kuskokwim (YK) Delta region have the highest reported respiratory syncytial virus (RSV) –associated hospitalization rate reported in the United States; however, there is no information about the contribution of RSV to acute respiratory infection (ARI) or respiratory exacerbation hospitalizations in Alaska Native adults. Adults in YK Delta have a high rate of respiratory hospitalizations; 77% of preventable hospitalizations are respiratory exacerbations of COPD. Adult RSV vaccines are in late-phase clinical trials and information about the contribution of RSV to adult respiratory hospitalization in Alaska Native people are a prerequisite to help design vaccine trials.

**Objectives:** Our main objective is to evaluate the contribution of RSV to hospitalized respiratory illness/exacerbations in adults by determining the #/% of adult respiratory-related hospitalizations which are RSV positive. We will also determine the contribution of RSV to respiratory exacerbations of adults with COPD or bronchiectasis and compare to the contribution from influenza. Importantly, we will determine the overall hospitalization rate associated with RSV infection in Alaska Native adults with underlying disease conditions.

**Methods:** After informed consent, we will obtain a NP swab on YK Delta adults 19+ years hospitalized at **YK Delta Regional Hospital** (12 adult beds) or **Alaska Native Medical Center** (~140 adult beds) with a respiratory illness or COPD exacerbation. NP swabs will be tested for RSV A and B as well as influenza A and B, parainfluenza, rhinovirus, coronavirus, adenovirus and human metapneumovirus using sensitive and specific reverse transcriptase singleplex polymerase chain reaction (PCR). We will swab consented adults weekly during hospitalization to evaluate duration of shedding, viral load and nosocomial spread of RSV. We will also conduct a short questionnaire of symptoms and perform a medical record review of hospitalizations, clinic visits and antibiotic use in the past 6 months and underlying conditions. We will also seek a waiver of informed consent to do a medical record review of a sample of de-identified adults 19-44 years, 45-64 years, and 65+ years of age to determine the proportion of YK Delta adults who have underlying medical conditions. Duration of project: We will conduct the study over a 2 year period. There are 75 bacterial pneumonia and 120 COPD exacerbation/asthma hospitalizations annually in YK Delta adults 19+ years, with an adult population of approximately 13,830.

**Data Management:** Denominator and basic hospital demographics for YK adults including length of stay will be obtained through census and YKDRH hospitalization data. Participant electronic health records will be reviewed for the current hospitalization duration and severity and for underlying medical conditions.

**Analysis:** Rates of LRTI and RSV hospitalization will be calculated and analysis performed for the following variables: age 19-49, 50-64, and 65+ years, sex, underlying COPD and other conditions, month of admission. The impact of viral load for each virus will be studied with respect to demographics including age, sex, severity of disease (mechanical ventilation, duration). Antibody concentrations in the sera will be compared to disease severity based on ARI diagnosis, hospital stay, and mechanical ventilation. Decline in viral load will be assessed by weekly assessment of RSV viral load in patients hospitalized for > 1 week.